Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) EBITDA: 2009-2025

Historic EBITDA for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to -$17.2 million.

  • Lifecore Biomedical's EBITDA rose 147.88% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$17.2 million, marking a year-over-year decrease of 181.17%. This contributed to the annual value of -$17.2 million for FY2025, which is 94.99% down from last year.
  • As of FY2025, Lifecore Biomedical's EBITDA stood at -$17.2 million, which was down 94.99% from -$8.8 million recorded in FY2024.
  • Lifecore Biomedical's 5-year EBITDA high stood at -$8.8 million for FY2021, and its period low was -$21.8 million during FY2023.
  • In the last 3 years, Lifecore Biomedical's EBITDA had a median value of -$17.2 million in 2025 and averaged -$16.0 million.
  • In the last 5 years, Lifecore Biomedical's EBITDA soared by 65.90% in 2021 and then crashed by 94.99% in 2025.
  • Lifecore Biomedical's EBITDA (Yearly) stood at -$8.8 million in 2021, then crashed by 33.64% to -$11.8 million in 2022, then plummeted by 84.85% to -$21.8 million in 2023, then soared by 59.42% to -$8.8 million in 2024, then plummeted by 94.99% to -$17.2 million in 2025.